EBOSY logo

EBOS Group Limited (EBOSY) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

EBOSY, $ (piyasa değeri 0) fiyatla Healthcare işi olan EBOS Group Limited'i temsil ediyor. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 42/100 (ihtiyatlı) olarak derecelendirilmiştir.

Son analiz: 16 Mar 2026
42/100 AI Puanı

EBOS Group Limited (EBOSY) Sağlık ve Boru Hattı Genel Bakışı

CEOAdam Luke Hall
Çalışanlar5200
MerkezDocklands, AU
Halka Arz Yılı2017
SektörHealthcare

EBOS Group Limited is a diversified healthcare and animal care products distributor in Australia, Southeast Asia, and New Zealand. With a wide range of products and services, EBOS operates through its Healthcare and Animal Care segments, providing healthcare logistics, medication management, and veterinary products, distinguishing itself through its integrated retail programs and extensive distribution network.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 16 Mar 2026

Yatırım Tezi

EBOS Group Limited presents a compelling investment case based on its diversified revenue streams and stable market position in the healthcare and animal care sectors. With a P/E ratio of 11.20 and a dividend yield of 7.05%, EBOS offers potential value and income. The company's growth is underpinned by its expansion in Southeast Asia and its established presence in Australia and New Zealand. Catalysts include ongoing expansion of its healthcare logistics and animal care product lines. Potential risks include regulatory changes in the healthcare sector and currency fluctuations affecting its international operations. The company's beta of 0.18 suggests lower volatility compared to the broader market.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Market capitalization of $1.67 billion, reflecting its established position in the healthcare and animal care sectors.
  • P/E ratio of 11.20, indicating a potentially undervalued investment relative to its earnings.
  • Dividend yield of 7.05%, offering a substantial income stream for investors.
  • Gross margin of 7.2%, reflecting the company's ability to manage its cost of goods sold.
  • Beta of 0.18, suggesting lower volatility compared to the overall market.

Rakipler & Benzerleri

Güçlü Yönler

  • Diversified revenue streams across healthcare and animal care.
  • Established distribution network in Australia, Southeast Asia, and New Zealand.
  • Integrated retail programs for independent pharmacies.
  • Strong relationships with suppliers and customers.

Zayıflıklar

  • Relatively low gross margin compared to industry peers.
  • Exposure to regulatory changes in the healthcare sector.
  • Dependence on key suppliers and customers.
  • Limited brand recognition outside of core markets.

Katalizörler

  • Ongoing: Expansion of healthcare logistics and distribution services in Southeast Asia.
  • Ongoing: Increased demand for animal care products driven by pet humanization trends.
  • Upcoming: Potential strategic acquisitions to expand product portfolio and geographic reach.
  • Ongoing: Development of innovative healthcare solutions, such as medication management software.
  • Ongoing: Growth in the vitamins, minerals, and supplements market.

Riskler

  • Potential: Regulatory changes in the healthcare sector impacting product approvals and pricing.
  • Potential: Economic downturns affecting consumer spending on healthcare and pet products.
  • Ongoing: Currency fluctuations impacting international operations.
  • Potential: Disruptions in the supply chain due to geopolitical events or natural disasters.
  • Potential: Intense competition from established players in the healthcare and animal care industries.

Büyüme Fırsatları

  • Expansion in Southeast Asia: EBOS has the opportunity to expand its presence in the growing Southeast Asian healthcare and animal care markets. The increasing demand for healthcare services and pet products in countries like Indonesia, Thailand, and Vietnam presents a significant growth opportunity. EBOS can leverage its existing distribution network and product portfolio to capture a larger market share. This expansion is expected to contribute to revenue growth over the next 3-5 years.
  • Increased Demand for Animal Care Products: The pet industry is experiencing significant growth, driven by the increasing humanization of pets and a greater focus on pet health and wellness. EBOS can capitalize on this trend by expanding its range of pet nutrition, treats, and grooming products. The company can also leverage its veterinary product distribution network to reach a wider customer base. This growth opportunity is expected to drive revenue growth in the animal care segment over the next 2-3 years.
  • Healthcare Logistics and Distribution: EBOS can further strengthen its position in healthcare logistics and distribution by expanding its warehousing and clinical trial management services. The increasing complexity of healthcare supply chains and the growing demand for clinical trials present a significant opportunity. EBOS can leverage its expertise and infrastructure to provide efficient and reliable logistics solutions to healthcare providers and pharmaceutical companies. This expansion is expected to contribute to revenue growth over the next 3-5 years.
  • Strategic Acquisitions: EBOS can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring companies in complementary sectors, such as specialty pharmaceuticals or veterinary services, can enhance EBOS's competitive position and drive revenue growth. The company can also target acquisitions in new geographic markets to expand its presence and diversify its revenue streams. These acquisitions are expected to contribute to revenue growth over the next 3-5 years.
  • Development of Innovative Healthcare Solutions: EBOS can invest in the development of innovative healthcare solutions, such as medication management software and telehealth services. The increasing adoption of digital health technologies presents a significant opportunity. EBOS can leverage its expertise and infrastructure to develop solutions that improve patient outcomes and streamline healthcare delivery. This development is expected to contribute to revenue growth over the next 3-5 years.

Fırsatlar

  • Expansion in Southeast Asia and other emerging markets.
  • Increased demand for animal care products.
  • Strategic acquisitions to expand product portfolio and geographic reach.
  • Development of innovative healthcare solutions.

Tehditler

  • Intense competition from established players in the healthcare and animal care industries.
  • Economic downturns affecting consumer spending on healthcare and pet products.
  • Currency fluctuations impacting international operations.
  • Disruptions in the supply chain due to geopolitical events or natural disasters.

Rekabet Avantajları

  • Extensive distribution network across Australia, Southeast Asia, and New Zealand.
  • Diversified product portfolio across healthcare and animal care sectors.
  • Integrated retail programs for independent pharmacies.
  • Long-standing relationships with suppliers and customers.

EBOSY Hakkında

EBOS Group Limited, originally founded in 1922 as Early Bros Dental & Surgical Supplies Ltd., has evolved into a diversified healthcare and animal care company. Headquartered in Docklands, Australia, EBOS operates across Australia, Southeast Asia, and New Zealand. The company's two main segments are Healthcare and Animal Care. The Healthcare segment provides healthcare logistics, medication management solutions, pharmacy management software, and a range of services including business intelligence and health communications. It also offers community-based healthcare services, vitamins, supplements, and functional foods. EBOS provides integrated retail programs for independent pharmacies, such as Pharmacy Choice and healthSAVE. The company supplies health and wellness products to hospitals, aged care facilities, and specialist clinics. The Animal Care segment provides pet nutrition, treats, grooming products, and veterinary products for companion and production animals. EBOS distributes allografts solutions, aesthetic healthcare devices, medical-grade cosmeceuticals, injectables, surgical devices, and medical consumables. The company changed its name to EBOS Group Limited in 1986, reflecting its expanded scope and strategic direction.

Ne Yaparlar

  • Markets, wholesales, and distributes healthcare products.
  • Markets, wholesales, and distributes medical products.
  • Markets, wholesales, and distributes pharmaceutical products.
  • Markets, wholesales, and distributes animal care products.
  • Provides healthcare logistics and medication management solutions.
  • Offers pharmacy management software and business intelligence services.
  • Supplies health and wellness products to hospitals and aged care facilities.

İş Modeli

  • Distribution of healthcare, medical, pharmaceutical, and animal care products to various customers.
  • Provision of healthcare logistics and medication management solutions.
  • Sales of vitamins, minerals, supplements, and functional foods.
  • Wholesaling of veterinary products for companion and production animals.

Sektör Bağlamı

EBOS Group Limited operates in the healthcare and animal care industries, which are experiencing steady growth driven by aging populations and increasing pet ownership. The healthcare sector is characterized by stringent regulations and high barriers to entry. EBOS competes with companies like ARSUF, DRWKF, EKTAF, IUSDF, and MEDGF, focusing on distribution and specialized services. The animal care industry is driven by pet humanization trends, with increasing demand for premium pet products and veterinary services. EBOS is positioned to benefit from these trends through its established distribution network and diversified product offerings.

Kilit Müşteriler

  • Public and private hospitals
  • Day surgeries and general practices
  • Aged care facilities
  • Specialist clinics
  • Veterinary clinics
AI Güveni: 72% Güncellendi: 16 Mar 2026

Finansallar

Grafik & Bilgi

EBOS Group Limited (EBOSY) hisse senedi fiyatı: Price data unavailable

Son Haberler

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

EBOSY için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

EBOSY için Wall Street fiyat hedefi analizi.

MoonshotScore

42/100

Bu puan ne anlama geliyor?

MoonshotScore, EBOSY'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: Adam Luke Hall

CEO

Adam Luke Hall is the CEO of EBOS Group Limited, managing a workforce of 5200 employees. His background includes extensive experience in the healthcare and pharmaceutical industries. Hall has held various leadership positions in multinational corporations, focusing on strategic planning, operational efficiency, and business development. He has a proven track record of driving growth and improving profitability. Hall's expertise spans across supply chain management, regulatory affairs, and market expansion.

Sicil: Under Adam Luke Hall's leadership, EBOS Group Limited has expanded its presence in Southeast Asia and strengthened its position in the Australian and New Zealand markets. He has overseen strategic acquisitions and partnerships that have enhanced the company's product portfolio and geographic reach. Hall has also focused on improving operational efficiency and implementing innovative healthcare solutions. His tenure has been marked by consistent revenue growth and improved profitability.

EBOS Group Limited ADR Bilgileri Sponsorsuz

An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. EBOSY functions as a Level 1 ADR, meaning it trades over-the-counter (OTC) without needing to meet the stringent listing requirements of exchanges like the NYSE or NASDAQ. This allows U.S. investors to invest in EBOS Group Limited more easily.

  • Ana Piyasa Sembolü: EBOS trades on the Australian Securities Exchange (ASX) under the ticker EBOS.
  • ADR Seviyesi: 1
  • ADR Oranı: 1:1
  • Ana Piyasa Sembolü: EBOS
Kur Riski: Investing in EBOSY exposes U.S. investors to currency risk, as the ADR's value is affected by fluctuations between the U.S. dollar and the Australian dollar. If the Australian dollar weakens against the U.S. dollar, the value of EBOSY may decrease, even if the underlying EBOS stock performs well in Australian dollar terms. Investors should monitor exchange rates.
Vergi Etkileri: U.S. investors in EBOSY may be subject to foreign dividend withholding taxes imposed by the Australian government. The standard withholding tax rate is 30%, but this may be reduced to 15% under the tax treaty between the U.S. and Australia. Investors may be able to claim a foreign tax credit on their U.S. tax return for the amount of foreign taxes withheld.
İşlem Saatleri: The Australian Securities Exchange (ASX) operates on Australian Eastern Standard Time (AEST), which is significantly different from U.S. trading hours. When the ASX is open, the U.S. markets are generally closed. This means U.S. investors may not be able to react immediately to news or events affecting EBOS during Australian trading hours, potentially leading to price discrepancies when the U.S. market opens.

EBOSY OTC Piyasa Bilgileri

EBOSY trades on the OTC Other tier, which represents the lowest tier of the OTC market. Companies on this tier may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. This tier is generally associated with higher risk and less transparency compared to stocks listed on major exchanges like the NYSE or NASDAQ. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.

  • OTC Katmanı: OTC Other
  • Açıklama Durumu: Unknown
Likidite: As an OTC Other stock, EBOSY is likely to have limited liquidity compared to stocks listed on major exchanges. This means trading volume may be low, and the bid-ask spread may be wide. It may be difficult for investors to buy or sell large quantities of EBOSY without significantly affecting the price. Investors should be aware of the potential for price volatility and trading difficulties when investing in EBOSY.
OTC Risk Faktörleri:
  • Limited liquidity and potential for price volatility.
  • Lack of transparency and limited financial disclosure.
  • Higher risk of fraud or manipulation compared to stocks listed on major exchanges.
  • Potential for delisting or suspension of trading.
  • Limited regulatory oversight and investor protection.
Durum Tespiti Kontrol Listesi:
  • Verify the company's financial statements and SEC filings (if any).
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's growth prospects and potential risks.
  • Check for any regulatory actions or legal proceedings against the company.
  • Monitor the company's news and press releases for any material developments.
  • Consult with a financial advisor before making any investment decisions.
Meşruiyet Sinyalleri:
  • EBOS Group Limited is an established company with a long operating history.
  • The company has a diversified revenue stream across healthcare and animal care sectors.
  • EBOS Group Limited is listed on the Australian Securities Exchange (ASX).
  • The company has a market capitalization of $1.67 billion.
  • EBOS Group Limited has a dividend yield of 7.05%.

EBOSY Healthcare Hisse Senedi SSS

EBOSY için değerlendirilmesi gereken temel faktörler nelerdir?

EBOS Group Limited (EBOSY) şu anda yapay zeka skoru 42/100, düşük puanı gösteriyor. Temel güçlü yan: Diversified revenue streams across healthcare and animal care.. İzlenmesi gereken birincil risk: Potential: Regulatory changes in the healthcare sector impacting product approvals and pricing.. Bu bir finansal tavsiye değildir.

EBOSY MoonshotScore'u nedir?

EBOSY şu anda MoonshotScore'da 42/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

EBOSY verileri ne sıklıkla güncellenir?

EBOSY fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler EBOSY hakkında ne diyor?

EBOSY için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

EBOSY'a yatırım yapmanın riskleri nelerdir?

EBOSY için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Regulatory changes in the healthcare sector impacting product approvals and pricing.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

EBOSY'ın P/E oranı nedir?

EBOSY için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için EBOSY'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

EBOSY aşırı değerli mi, yoksa düşük değerli mi?

EBOS Group Limited (EBOSY)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

EBOSY'ın temettü verimi nedir?

EBOS Group Limited (EBOSY) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • AI analysis pending for EBOSY. Analyst consensus and valuation metrics are based on historical data and industry averages.
  • Risk factors are based on general industry trends and company-specific information.
Veri Kaynakları

Popüler Hisseler